State Street Holds 7% Of Sarepta As The Drugmaker Faces Weaker Sales

Sarepta raised its product-revenue forecast floor by $50 million despite lower third-quarter and year-to-date sales.

Share
State Street Holds 7% Of Sarepta As The Drugmaker Faces Weaker Sales

State Street reported a 7% stake in Sarepta Therapeutics, which develops genetic medicines for rare diseases, in an SEC ownership filing Tuesday. The passive holding comes against a backdrop of falling sales, even as Sarepta raised the lower end of its annual product-revenue forecast.

A Passive Holding, Shared Votes

State Street's reported position totaled 7,412,275 common shares as of September 30, 2026. Its 7% ownership figure uses the SEC's beneficial-ownership basis, which measures ownership rights over the shares.

State Street reported shared voting power over 7,135,106 shares and zero sole voting power. It also reported shared power to dispose of 7,412,275 shares.

The company certified that the securities were bought and held as part of ordinary business activity, rather than for changing or influencing Sarepta's control.

Lower Sales, Higher Forecast Floor

Sarepta's third-quarter 2026 revenue was $381.4 million, below the year-earlier level. Revenue for the year to date also declined from the corresponding prior-year period.

Sarepta nevertheless lifted the bottom of its 2026 net product-revenue forecast by $50 million, putting the range at $1.25 billion–$1.3 billion. Management expects ELEVIDYS revenue in the second half to be modestly below the first half.

Shareholders' year-to-date total return was negative 17.19% through November 6, 2026. Sarepta's market value was $1.8 billion in Tuesday trading as of 9:58 a.m. ET.

Duchenne Treatments Anchor Sarepta's Business

Sarepta sells four approved Duchenne muscular dystrophy treatments: EXONDYS 51, VYONDYS 53, AMONDYS 45 and ELEVIDYS. The first three reach U.S. patients through home-infusion specialty pharmacies and a distributor serving hospitals and their outpatient clinics; ELEVIDYS reaches hospitals through logistics providers and specialty pharmacies.

Net product sales totaled $1.9 billion in 2025. Sarepta also licenses ELEVIDYS to Roche outside the U.S. and works with Arrowhead on an siRNA program aimed at diseases including facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.

Sources

More on Sarepta Therapeutics

All Sarepta Therapeutics (SRPT) coverage →